만성 간부전 급성 악화(ACLF) 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 예측 기간 동안 예상되는 성장은 간 지원 장치의 채택 증가, 재생 의학의 발전, 정밀 의학에 대한 강조 증가, 최소 침습 치료에 대한 수요 증가, 표적 치료법 개발, 신흥 시장의 의료 인프라 확장, 연구 개발에 대한 투자 증가, 대사 장애의 유병률 증가, 민관 파트너십 강화에 기인 할 수 있습니다. 이 기간에 예상되는 주요 트렌드에는 진단에 인공지능의 통합, 생명공학 간 조직의 개발, 체외 간 지원 장치의 발전, 개인화된 치료 계획을 위한 기계 학습의 사용, 유전자 편집 기술의 출현, 액체 생검 기술의 발전, 표적 약물 전달 시스템의 개발, 간 재생을 위한 3D 바이오 프린팅의 발전, 웨어러블 건강 모니터링 장치의 채택, 나노 기술 기반 치료의 혁신 등이 있습니다.
정밀의료와 개별화의료가 중시되게 된 것으로, 향후 수년간, 만성 간부전 급성 악화(ACLF) 시장의 확대가 전망됩니다. 이러한 접근법의 이용이 증가하고 있는 배경에는 유전체학의 진보, 바이오마커에 근거한 진단법의 이용 가능성의 확대, 데이터 분석 기술의 향상, 보다 적정한 효과적인 치료법에 대한 수요 증가짐이 있습니다. ACLF의 맥락에서 정밀 및 맞춤 의료는 환자의 유전자 프로필, 질병 중증도, 바이오마커 인사이트를 기반으로 맞춤형 치료를 가능하게 하여 결과를 개선하고 다장기 부전의 위험을 줄이는 표적 치료로 이어집니다. 예를 들어, 2024년 2월, 미국에 본사를 둔 비영리 단체인 개인 맞춤형 의약품 연합(PMC)은 미국 식품의약국(FDA)이 2023년에 26개의 새로운 개인 맞춤형 의약품을 승인했으며, 이는 2022년에 승인된 12개보다 현저히 증가한 수치라고 보고했습니다. 그 결과, 정밀 의학 및 개인 맞춤형 의약품에 대한 관심이 높아지면서 만성 간부전 급성 악화(ACLF) 시장의 성장에 크게 기여하고 있습니다.
만성 간부전 급성 악화(ACLF) 시장의 주요 기업은 환자의 생존율 향상을 목적으로 한 혁신적인 치료제, 재생 의료 접근법, 표적 약물 요법을 개발하기 위해 임상시험을 우선하고 있습니다. 임상시험은 질병 관리를 개선하고 사망률을 저하시켰습니다 새로운 치료 프로토콜, 인공 간 지원 시스템, 면역 조절 요법을 검증하는 데 중요한 역할을 하고 있습니다. 예를 들어, 2024년 9월 스페인에 본사를 둔 EU Horizon 지원 프로젝트인 A-TANGO는 영국의 여러 간 센터에서 'G-TAK 시험'을 실시할 계획을 발표했습니다. 이 임상시험은 알코올성 간염과 ACLF로 고통받는 중증 환자를 돕기 위해 고안되었습니다. G-TAK은 염증을 감소시키는 톨유사수용체4 길항제(TAK242)와 간세포 증식을 촉진하는 과립구 콜로니 자극인자(G-CSF, TRL9)를 결합하여 ACLF의 잠재적 치료법을 제공하는 병용 요법입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계의 만성 간부전 급성 악화(ACLF)(ACLF) PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
- 최종 이용 산업의 분석
- 세계의 만성 간부전 급성 악화(ACLF) 시장 :성장률 분석
- 세계의 만성 간부전 급성 악화(ACLF) 시장 실적 : 규모와 성장(2019-2024년)
- 세계의 만성 간부전 급성 악화(ACLF) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
- 세계의 만성 간부전 급성 악화(ACLF) 전체 시장(TAM)
제6장 시장 세분화
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 약리학
- 지원 치료
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 투여 방법별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 경구
- 정맥주사(IV)
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 병원
- 외래수술센터(ASC)
- 전문 클리닉
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 약리학 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 항생제
- 항염증제
- 혈관확장제
- 면역조절제
- 항바이러스제
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 지원 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 간 투석
- 혈장 교환
- 영양 지원
- 기계 환기
- 신장 대체 요법(RRT)
제7장 지역별/국가별 분석
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
- 세계의 만성 간부전 급성 악화(ACLF) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
- 만성 간부전 급성 악화(ACLF) 시장 : 경쟁 구도
- 만성 간부전 급성 악화(ACLF) 시장 : 기업 프로파일
- Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
- Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
- Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
- Bristol-Myers Squibb
- AstraZeneca plc
- Abbott Laboratories
- GSK plc
- Eli Lilly and Company
- Gilead Sciences Inc
- Novo Nordisk A/S
- Astellas Pharma Inc.
- CSL Behring
- Grifols SA
- Lupin Pharmaceutical Limited
- Ferring Pharmaceuticals
- Shire plc
- Gyre Therapeutics Inc.
- Dr. Falk Pharma GmbH
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 만성 간부전 급성 악화(ACLF) 시장(2029년) : 새로운 기회를 제공하는 국가
- 만성 간부전 급성 악화(ACLF) 시장(2029년) : 새로운 기회를 제공하는 부문
- 만성 간부전 급성 악화(ACLF) 시장(2029년) : 성장 전략
제36장 부록
KTH
Acute on chronic liver failure (ACLF) is a critical condition marked by acute hepatic decompensation in individuals with underlying chronic liver disease. This decline triggers widespread inflammation, leading to the progressive failure of multiple organs. The condition carries a high mortality risk, necessitating quick diagnosis and aggressive medical intervention.
Treatment options for acute on chronic liver failure (ACLF) primarily consist of pharmacological and supportive care. Pharmacological treatments involve the administration of drugs such as antibiotics, vasopressors, corticosteroids, albumin therapy, and liver-specific medications to manage infections, reduce inflammation, support organ function, and stabilize the patient in preparation for possible liver transplantation. These treatments can be delivered through oral or intravenous (IV) routes, and are provided in settings such as hospitals, ambulatory surgical centers, and specialty clinics.
The acute on chronic liver failure (ACLF) market research report is one of a series of new reports from The Business Research Company that provides acute on chronic liver failure (ACLF) market statistics, including acute on chronic liver failure (ACLF) industry global market size, regional shares, competitors with an acute on chronic liver failure (ACLF) market share, detailed acute on chronic liver failure (ACLF) market segments, market trends and opportunities, and any further data you may need to thrive in the acute on chronic liver failure (ACLF) industry. This acute on chronic liver failure (ACLF) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute on chronic liver failure (ACLF) market size has grown strongly in recent years. It will grow from $2.68 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth observed during the historic period can be linked to factors such as the increasing prevalence of chronic liver diseases, heightened awareness about liver health, growing healthcare spending, the development of new therapies, the rising incidence of alcohol-related liver damage, an increase in organ transplant procedures, advancements in critical care, a growing aging population, and expanded research into the mechanisms of liver failure.
The acute on chronic liver failure (ACLF) market size is expected to see strong growth in the next few years. It will grow to $3.89 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth during the forecast period can be attributed to the increasing adoption of liver support devices, advancements in regenerative medicine, a growing emphasis on precision medicine, rising demand for minimally invasive treatments, the development of targeted therapies, the expansion of healthcare infrastructure in emerging markets, increased investment in research and development, the rising prevalence of metabolic disorders, and the strengthening of public-private partnerships. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of bioengineered liver tissue, advancements in extracorporeal liver support devices, the use of machine learning for personalized treatment plans, the emergence of gene editing technologies, progress in liquid biopsy techniques, the creation of targeted drug delivery systems, advancements in 3D bioprinting for liver regeneration, the adoption of wearable health monitoring devices, and innovations in nanotechnology-based therapies.
The growing emphasis on precision and personalized medicine is expected to drive the expansion of the acute-on-chronic liver failure (ACLF) market in the coming years. Precision and personalized medicine involve tailoring treatments to individual patients based on genetic, environmental, and lifestyle factors to enhance outcomes and improve care. The increasing use of these approaches is attributed to advancements in genomics, the growing availability of biomarker-based diagnostics, improved data analytics technologies, and the rising demand for more targeted and effective therapies. In the context of ACLF, precision and personalized medicine enable customized treatments based on a patient's genetic profile, disease severity, and biomarker insights, leading to targeted therapies that improve outcomes and reduce the risk of multi-organ failure. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from the 12 approved in 2022. As a result, the increasing focus on precision and personalized medicine is significantly contributing to the growth of the ACLF market.
Leading companies in the ACLF market are prioritizing clinical trials to develop innovative therapeutics, regenerative medicine approaches, and targeted drug therapies aimed at enhancing patient survival rates. Clinical trials play a vital role in validating new treatment protocols, artificial liver support systems, and immunomodulatory therapies to improve disease management and lower mortality rates. For instance, in September 2024, A-TANGO, a Spain-based EU Horizon-funded project, announced plans to conduct the "G-TAK trial" across multiple liver centers in the UK. This trial is designed to assist critically ill patients suffering from alcoholic hepatitis and ACLF. G-TAK is a combinatorial therapy that includes a toll-like receptor 4 antagonist (TAK242) to reduce inflammation, combined with granulocyte colony-stimulating factor (G-CSF, TRL9) to promote hepatocyte proliferation, thereby offering a potential treatment for ACLF.
In September 2022, Genfit, a France-based late-stage biopharmaceutical company, acquired Versantis for $116 million. This acquisition reinforces Genfit's position in the ACLF market by incorporating a clinically advanced asset with promising Phase Ib and preclinical data, expanding its liver disease pipeline, and utilizing Versantis' expertise to accelerate research and development efforts. Versantis, a Switzerland-based clinical-stage biotechnology company, focuses on addressing the growing unmet medical needs in liver diseases, including ACLF.
Major players in the acute on chronic liver failure (aclf) market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Gilead Sciences Inc, Novo Nordisk A/S, Astellas Pharma Inc., CSL Behring, Grifols S.A., Lupin Pharmaceutical Limited, Ferring Pharmaceuticals, Shire plc, Gyre Therapeutics Inc., Dr. Falk Pharma GmbH, Genfit, eGenesis Inc., Conatus Pharmaceuticals Inc., Cellaion SA, Rheacell GmbH & Co. KG, Martin Pharmaceuticals Inc.
North America was the largest region in the acute on chronic liver failure (ACLF) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in acute on chronic liver failure (ACLF) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute on chronic liver failure (ACLF) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute on chronic liver failure (ACLF) market consists of revenues earned by entities by providing services such as diagnostic evaluations, intensive care management, liver function monitoring, hemodialysis, extracorporeal liver support therapies, nutritional support, palliative care and liver transplantation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute on chronic liver failure (ACLF) market also includes sales of diagnostic tools and liver support devices aimed at managing disease progression and improving patient outcomes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Acute On Chronic Liver Failure (ACLF) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute on chronic liver failure (aclf) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for acute on chronic liver failure (aclf) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The acute on chronic liver failure (aclf) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type Of Treatment: Pharmacological; Supportive Care
- 2) By Mode Of Administration: Oral; Intravenous (IV)
- 3) By End-User: Hospitals; Ambulatory Surgical Centers; Specialty Clinics
- Subsegments:
- 1) By Pharmacological: Antibiotics; Anti-inflammatory Drugs; Vasopressors; Immunomodulators; Antiviral Agents
- 2) By Supportive Care: Liver Dialysis; Plasma Exchange; Nutritional Support; Mechanical Ventilation; Renal Replacement Therapy (RRT)
- Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Bayer AG; Sanofi S.A.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Acute On Chronic Liver Failure (ACLF) Market Characteristics
3. Acute On Chronic Liver Failure (ACLF) Market Trends And Strategies
4. Acute On Chronic Liver Failure (ACLF) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Acute On Chronic Liver Failure (ACLF) Growth Analysis And Strategic Analysis Framework
- 5.1. Global Acute On Chronic Liver Failure (ACLF) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Acute On Chronic Liver Failure (ACLF) Market Growth Rate Analysis
- 5.4. Global Acute On Chronic Liver Failure (ACLF) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Acute On Chronic Liver Failure (ACLF) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Acute On Chronic Liver Failure (ACLF) Total Addressable Market (TAM)
6. Acute On Chronic Liver Failure (ACLF) Market Segmentation
- 6.1. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pharmacological
- Supportive Care
- 6.2. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Intravenous (IV)
- 6.3. Global Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- 6.4. Global Acute On Chronic Liver Failure (ACLF) Market, Sub-Segmentation Of Pharmacological, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antibiotics
- Anti-inflammatory Drugs
- Vasopressors
- Immunomodulators
- Antiviral Agents
- 6.5. Global Acute On Chronic Liver Failure (ACLF) Market, Sub-Segmentation Of Supportive Care, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Liver Dialysis
- Plasma Exchange
- Nutritional Support
- Mechanical Ventilation
- Renal Replacement Therapy (RRT)
7. Acute On Chronic Liver Failure (ACLF) Market Regional And Country Analysis
- 7.1. Global Acute On Chronic Liver Failure (ACLF) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Acute On Chronic Liver Failure (ACLF) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market
- 8.1. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Acute On Chronic Liver Failure (ACLF) Market
- 9.1. China Acute On Chronic Liver Failure (ACLF) Market Overview
- 9.2. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Acute On Chronic Liver Failure (ACLF) Market
- 10.1. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Acute On Chronic Liver Failure (ACLF) Market
- 11.1. Japan Acute On Chronic Liver Failure (ACLF) Market Overview
- 11.2. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Acute On Chronic Liver Failure (ACLF) Market
- 12.1. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Acute On Chronic Liver Failure (ACLF) Market
- 13.1. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Acute On Chronic Liver Failure (ACLF) Market
- 14.1. South Korea Acute On Chronic Liver Failure (ACLF) Market Overview
- 14.2. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Acute On Chronic Liver Failure (ACLF) Market
- 15.1. Western Europe Acute On Chronic Liver Failure (ACLF) Market Overview
- 15.2. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Acute On Chronic Liver Failure (ACLF) Market
- 16.1. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Acute On Chronic Liver Failure (ACLF) Market
- 17.1. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Acute On Chronic Liver Failure (ACLF) Market
- 18.1. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Acute On Chronic Liver Failure (ACLF) Market
- 19.1. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Acute On Chronic Liver Failure (ACLF) Market
- 20.1. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market
- 21.1. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market Overview
- 21.2. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Acute On Chronic Liver Failure (ACLF) Market
- 22.1. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Acute On Chronic Liver Failure (ACLF) Market
- 23.1. North America Acute On Chronic Liver Failure (ACLF) Market Overview
- 23.2. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Acute On Chronic Liver Failure (ACLF) Market
- 24.1. USA Acute On Chronic Liver Failure (ACLF) Market Overview
- 24.2. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Acute On Chronic Liver Failure (ACLF) Market
- 25.1. Canada Acute On Chronic Liver Failure (ACLF) Market Overview
- 25.2. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Acute On Chronic Liver Failure (ACLF) Market
- 26.1. South America Acute On Chronic Liver Failure (ACLF) Market Overview
- 26.2. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Acute On Chronic Liver Failure (ACLF) Market
- 27.1. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Acute On Chronic Liver Failure (ACLF) Market
- 28.1. Middle East Acute On Chronic Liver Failure (ACLF) Market Overview
- 28.2. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Acute On Chronic Liver Failure (ACLF) Market
- 29.1. Africa Acute On Chronic Liver Failure (ACLF) Market Overview
- 29.2. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Type Of Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Acute On Chronic Liver Failure (ACLF) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Acute On Chronic Liver Failure (ACLF) Market Competitive Landscape And Company Profiles
- 30.1. Acute On Chronic Liver Failure (ACLF) Market Competitive Landscape
- 30.2. Acute On Chronic Liver Failure (ACLF) Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Acute On Chronic Liver Failure (ACLF) Market Other Major And Innovative Companies
- 31.1. Bristol-Myers Squibb
- 31.2. AstraZeneca plc
- 31.3. Abbott Laboratories
- 31.4. GSK plc
- 31.5. Eli Lilly and Company
- 31.6. Gilead Sciences Inc
- 31.7. Novo Nordisk A/S
- 31.8. Astellas Pharma Inc.
- 31.9. CSL Behring
- 31.10. Grifols S.A.
- 31.11. Lupin Pharmaceutical Limited
- 31.12. Ferring Pharmaceuticals
- 31.13. Shire plc
- 31.14. Gyre Therapeutics Inc.
- 31.15. Dr. Falk Pharma GmbH
32. Global Acute On Chronic Liver Failure (ACLF) Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Acute On Chronic Liver Failure (ACLF) Market
34. Recent Developments In The Acute On Chronic Liver Failure (ACLF) Market
35. Acute On Chronic Liver Failure (ACLF) Market High Potential Countries, Segments and Strategies
- 35.1 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Acute On Chronic Liver Failure (ACLF) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
